Novartis Biopharm Manufacturing Starts in Singapore

Novartis Biopharm Manufacturing Starts in Singapore

By, Admin 19 March 2024

Novartis Expands Biopharmaceutical Manufacturing Facility in Singapore

Overview

Novartis has commenced the expansion of its biopharmaceutical manufacturing plant in Singapore, announcing a significant investment of US$256 million. This expansion aims to integrate digital and automation solutions to enhance manufacturing productivity, operational efficiency, and workforce skills. The focus of the expanded site will be on producing therapeutic antibody drugs to provide groundbreaking treatments to patients worldwide.

Emphasis on Innovation

  • Mr. Heng Swee Keat, Deputy Prime Minister and Coordinating Minister for Economic Policies, emphasized the importance of continuous innovation in manufacturing for the biopharma sector. 
  • He highlighted Singapore's well-established biomedical ecosystem, expressing confidence in collaboration with global partners like Novartis to deliver innovative biologics products.

Novartis on Biopharmaceutical Supply Chain

  • Steffen Lang, President of Operations at Novartis, underscored the growing significance of biotherapeutics in addressing patient needs. 
  • He mentioned the substantial growth in Novartis' early-stage biologics portfolio and emphasized the timely nature of the new facility in Singapore, slated to be operational by early 2026. 
  • Lang highlighted its role in strengthening the biopharmaceutical manufacturing and supply chain across Asia, as well as enhancing local capabilities and talent in Singapore.

Generating Jobs

  • The endeavor is expected to create 100 high-skilled job openings, contributing to the expansion of the local life science sector. 
  • Novartis is committed to investing in talent development, providing training for existing employees to excel in the digitalized and automated environment of the expanded facility.

The Guest-of-Honor

The groundbreaking event was graced by Deputy Prime Minister Heng Swee Keat as the Guest-of-Honor, along with Frank Grütter, Swiss Ambassador to Singapore, and Ms. Cindy Koh, Executive Vice President of EDB, among others.

Novartis Efforts 

  • Novartis has maintained a strong partnership with Singapore since 1986, with over US$1 billion invested to uplift the nation's pharmaceutical manufacturing capabilities. 
  • The Novartis Singapore manufacturing site, established since 2002, has been pivotal in the company's biopharmaceutical production efforts, supported by the Singapore government.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!